Accelerating hydroxyurea adoption for sickle cell disease in Nigeria
Official title: mAnaging siCkle CELl disease through incReased AdopTion of hydroxyurEa in Nigeria (ACCELERATE)
Funded at New York University · NIH-11415723 · Data updated 2026-11-12
A pragmatic study in Nigeria aims to help more people with sickle cell disease get hydroxyurea, a treatment that reduces painful crises and hospitalizations.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $438,160 |
| NIH project number | 5U01HL168084-04 |
| Project ID | NIH-11415723 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and children with sickle cell disease in Nigeria who are eligible for hydroxyurea and receive care in participating clinics.
✕Less likely to help
Patients not yet eligible for hydroxyurea or not receiving care in participating sites may not benefit directly.
What this research studies
This project works in Nigeria to find practical ways to increase how often doctors prescribe hydroxyurea for people with sickle cell disease. It tests real-world strategies in clinics and health systems to support providers and sustain HU delivery. The findings could also inform how similar gaps are addressed in the United States, especially in rural and underserved care settings. The study is designed as a pragmatic trial that focuses on implementation and scale within existing healthcare infrastructure.
Why it matters
Potential benefit: If successful, patients with sickle cell disease could experience fewer painful episodes, fewer hospital visits, and better overall health through improved access to hydroxyurea.
How similar studies have gone: Previous studies show HU is effective; this project tests practical implementation strategies to increase real-world use.
Where this research is happening
-
New York University
New York, United States Active
Researchers
- Principal investigator: Peprah, Emmanuel K — New York University
- Study coordinator: Peprah, Emmanuel K
Related research
Other NIH-funded projects on the same topics.
-
Digital twins of the spleen to help design better therapies for sickle cell disease
A computer-driven replica of the spleen is being developed to speed up creating safer and more effective treatments for people with sickle cell disease.
-
Accelerating hydroxyurea use for sickle cell disease in Nigeria
A pragmatic study in Nigeria aims to help doctors use hydroxyurea more consistently for people with sickle cell disease.
-
Immune and nerve signals behind acupuncture relief for sickle cell pain
This NIH grant explores how acupuncture helps reduce pain and opioid use for people with sickle cell disease.
-
Mindfulness-based Support for Pain and Sleep in Young People with Sickle Cell Disease
A digital mindfulness program is being tailored for adolescents and young adults with sickle cell disease to help with pain and sleep and is being tested for practicality and early effectiveness.
-
How diet affects white blood cells and sickle cell disease
A study looks at how nutrition, from early life to adulthood, influences sickle cell disease by examining neutrophils and disease severity in people with SCD and in a mouse model.
-
Nutrition-based plan to ease pain in sickle cell disease
A nutrition-based approach is being tested to reduce pain for people living with sickle cell disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.